LEVOXYL Drug Patent Profile

When do Levoxyl patents expire, and when can generic versions of Levoxyl launch?

Levoxyl is a drug marketed by King Pharms and is included in one NDA.

The generic ingredient in LEVOXYL is levothyroxine sodium. There are ten drug master file entries for this compound. Fifty-five suppliers are listed for this compound. Additional details are available on the levothyroxine sodium profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Levoxyl

A generic version of LEVOXYL was approved as levothyroxine sodium by MYLAN on June 5^th, 2002.

Summary for LEVOXYL

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	1
Patent Applications:	2,577
Drug Prices:	Drug price information for LEVOXYL
Drug Sales Revenues:	Drug sales revenues for LEVOXYL
What excipients (inactive ingredients) are in LEVOXYL?	LEVOXYL excipients list
DailyMed Link:	LEVOXYL at DailyMed

See drug prices for LEVOXYL

See drug sales revenues for LEVOXYL

Recent Clinical Trials for LEVOXYL

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	N/A
Children's Hospital of Philadelphia	N/A

See all LEVOXYL clinical trials

Pharmacology for LEVOXYL

Drug Class

l-Thyroxine

US Patents and Regulatory Information for LEVOXYL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
King Pharms	LEVOXYL	levothyroxine sodium	TABLET;ORAL	021301-001	May 25, 2001	AB1,AB3	RX	Yes	No
King Pharms	LEVOXYL	levothyroxine sodium	TABLET;ORAL	021301-007	May 25, 2001	AB1,AB3	RX	Yes	No
King Pharms	LEVOXYL	levothyroxine sodium	TABLET;ORAL	021301-004	May 25, 2001	AB1,AB3	RX	Yes	No
King Pharms	LEVOXYL	levothyroxine sodium	TABLET;ORAL	021301-012	May 25, 2001		DISCN	Yes	No

Expired US Patents for LEVOXYL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
King Pharms	LEVOXYL	levothyroxine sodium	TABLET;ORAL	021301-005	May 25, 2001
King Pharms	LEVOXYL	levothyroxine sodium	TABLET;ORAL	021301-005	May 25, 2001
King Pharms	LEVOXYL	levothyroxine sodium	TABLET;ORAL	021301-008	May 25, 2001
King Pharms	LEVOXYL	levothyroxine sodium	TABLET;ORAL	021301-002	May 25, 2001

International Patents for LEVOXYL

See the table below for patents covering LEVOXYL around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2002240394
Australia	2002258397
Australia	2002332507
Australia	2002341555

Last updated: April 25, 2026

LEVOXYL (levothyroxine sodium) — Market Dynamics and Financial Trajectory

What is LEVOXYL and how is it positioned in the market?

LEVOXYL is a brand formulation of levothyroxine sodium, a synthetic thyroid hormone used to treat hypothyroidism. In the US market, levothyroxine products sit in a mature, highly price-pressured category driven by (1) long-duration chronic use, (2) generic substitution dynamics, (3) wholesale and pharmacy distribution incentives, and (4) payer and pharmacy formulary behavior around “brand vs generic” switching and dose uniformity.

The product’s market behavior is shaped less by patent exclusivity and more by:

• Bioequivalence expectations for levothyroxine products and resultant payer preference for generics.
• Formulation continuity and prescriber/patient resistance to switching when stable control is maintained.
• Supply chain and inventory planning that determines whether brand supply shortages translate into temporary share gains or gaps that generics cover.

How does competition define LEVOXYL’s market dynamics?

LEVOXYL’s competitive set is primarily generic levothyroxine sodium tablets in multiple strengths, plus other branded levothyroxine products historically available in the US (for example, Synthroid). In this category, price pressure and formulary placement dominate the share curve.

Key dynamics:

1. Generic substitution

   • Levothyroxine is one of the most widely substituted drug classes in the US due to extensive generic penetration.
   • Payer steerage to generics compresses realized net prices for brands over time.

2. Therapeutic switching friction

   • Even where products are considered interchangeable at the clinical level, prescribers and patients often resist switching when patients are stable.
   • That friction can temporarily sustain brand loyalty, but it does not prevent long-run price erosion.

3. Contracting and channel economics

   • Brand pricing tends to be shaped by pharmacy benefit manager (PBM) rebates, wholesaler contracting, and pharmacy reimbursement dynamics.
   • In mature categories, observed brand “revenue” often tracks trade dynamics as much as volume.

What are the main demand drivers for levothyroxine brands like LEVOXYL?

Demand is steady and anchored to chronic care:

• Hypothyroidism prevalence and stable prescribing patterns drive volume.
• Dose-specific continuity matters because levothyroxine dosing is titration-based and patients can require long-term stability.
• Adherence for chronic therapy is generally high, which reduces unit volatility versus acute therapeutic areas.

As a result, LEVOXYL’s revenue curve typically reflects:

• Gradual brand share erosion as generics gain shelf and formulary position, and
• Net price compression driven by contracting, rebates, and payer preferences.

What does LEVOXYL’s financial trajectory typically look like in a generic-heavy category?

For brands in mature, substitution-prone products, financial trajectory usually follows a recognizable pattern:

• Peak-to-decline behavior once generic entry expands and formulary preferences shift further toward generics.
• Volume stability with price decline, as brand units can remain resilient due to switching friction, but realized price falls.
• Revenue volatility tied to channel movements (inventory, reimbursement updates, contracting cycles) rather than underlying incidence changes.

In levothyroxine, that pattern is common because the category is mature and demand is chronic.

Where do revenues come from: unit sales vs realized net price?

For LEVOXYL and comparable levothyroxine brands, revenue changes usually decompose into two forces:

Revenue driver	Typical direction in mature levothyroxine	Market mechanism
Realized net price	Down over time	PBM and payer contracting, increased generic pressure, rebate compression and shift
Units / prescriptions	Mostly flat to slowly down	Switching friction supports baseline, but generic substitution limits incremental share

How does payer policy impact LEVOXYL’s earning power?

Payer policy influences both:

• Placement (preferred brand vs non-preferred brand), and
• Patient-level access (tier placement, prior authorization triggers, step edits, and co-pay design).

In levothyroxine, payer strategies generally prioritize cost containment while managing the risk of destabilizing switching. This can create a dynamic where brands retain a minimum presence but cannot materially re-expand share without broader payer changes.

What role do wholesalers and distribution play?

Pharmacy and wholesaler behavior influences short-run revenue recognition:

• Inventory build in advance of contracting cycles can temporarily support shipments.
• Conversely, corrections after demand forecasting errors can depress reported volume even if prescriptions remain stable.

For a chronic therapy, these effects show up as revenue “wiggle” around a largely stable underlying demand base.

What is LEVOXYL’s strategic implication for R&D and commercial planning?

Because levothyroxine is not a high-innovation therapeutic area, the competitive strategy for brands is commercial and operational:

• Maintain reliable supply across strengths to avoid channel disruption.
• Protect continuity of dosing by strengthening prescriber familiarity and adherence programs.
• Optimize contracting and formulary strategy within PBM and plan constraints.

For investors and R&D strategists, the key is that LEVOXYL competes primarily on access economics rather than differentiation in clinical outcomes.

---

Financial Trajectory: What the market structure implies for LEVOXYL

Without product-specific financial statements in the provided dataset, the only defensible “financial trajectory” is category-logic based. For a levothyroxine brand like LEVOXYL in a generic-heavy US environment, the trajectory is:

• Downward realized price trend driven by sustained generic substitution.
• Limited unit downside due to stable chronic demand and switching friction.
• Revenue dependence on contracting cycles that determine net pricing and channel inventory levels.

This is the dominant shape for long-running thyroid hormone brands facing persistent generic pressure.

---

Key Takeaways

• LEVOXYL’s market is mature and substitution-driven: chronic demand supports baseline volume, but generic levothyroxine pressure drives long-run price compression.
• Revenue is primarily a net price story with smaller contribution from units, shaped by PBM and payer contracting.
• Short-run fluctuations usually reflect trade and contracting dynamics, not changes in hypothyroidism incidence.
• The commercial objective is continuity of access and reliable supply rather than breakthrough clinical differentiation.

---

FAQs

1. Is LEVOXYL still competitive in the US given generic levothyroxine?
   Yes in a limited sense: switching friction and dose continuity can sustain baseline access, but long-run growth is constrained by generic substitution.

2. What most affects LEVOXYL realized revenue?
   PBM and payer contracting that drives net price, plus channel inventory behavior around contracting cycles.

3. Does chronic use make demand more stable?
   Yes. Hypothyroidism treatment is typically long-duration, which reduces unit volatility versus acute therapies.

4. How do payer decisions influence brand vs generic share?
   Formulary placement, copay/tier design, and step edits determine patient and prescriber behavior toward generic substitution.

5. What operational factor can move brand performance quickly?
   Supply continuity across strengths. Stock issues can shift patients to alternatives and can take time to reverse.

---

References

[1] FDA. “Levothyroxine sodium” and related product information (drug labeling and regulatory references). U.S. Food and Drug Administration.
[2] FDA. “Approved Drug Products with Therapeutic Equivalence Evaluations” (Orange Book). U.S. Food and Drug Administration.
[3] StatPearls. “Hypothyroidism” and thyroid hormone replacement overview (clinical context for levothyroxine use). StatPearls Publishing.
[4] AHRQ/Agency for Healthcare Research and Quality. Evidence and policy material relevant to generic substitution and medication switching considerations (policy and clinical context). Agency for Healthcare Research and Quality.

DrugChatter Q&A for LEVOXYL

Levoxyl inactive ingredients?